摘要
目的探讨Zeste同源增强子2（EZH2）和p53蛋白在宫颈鳞状细胞癌（SCC）及癌前病变中的表达及临床意义。方法采用链霉卵白素-过氧化物酶连结（SP）免疫组化方法，检测SCC（168例）、宫颈上皮内瘤样病变（CIN）Ⅱ（19例）、CINⅢ（35例）和正常宫颈（30例）组织中EZH2和p53蛋白的表达情况，分析EZH2和p53蛋白共同表达的关系以及EZH2和p53蛋白表达与SCC临床病理特征和预后的关系。结果在正常宫颈、CIN、SCC组织中，EZH2蛋白的阳性表达率分别为6．7％（2／30）、37．O％（20／54）和75．6％（127／168），p53蛋白的阳性表达率分别为3．3％（1／30）、20．4％（11／54）和39．3％（66／168），差异均有统计学意义（均P〈0．05）。168例SCC患者中，有淋巴结转移患者的EZH2和p53蛋白阳性表达率分别为82．9％和45．7％，无淋巴结转移患者的EZH2和p53蛋白阳性表达率分别为70．4％和34．7％，差异有统计学意义（P〈0．05）。随访的143例SCC患者中，EZH2和p53阴性、EZH2或p53阳性、EZH2和p53阳性患者的肿瘤无进展生存时间（PFS）分别为（71．3±1．9）个月、（66．1±2．0）个月和（51．3±3．8）个月，三者间差异有统计学意义（P〈0．001）。EZH2和p53阴性、EZH2或p53阳性、EZH2和p53阳性患者的总生存时间（OS）分别为（72．9±1．1）个月、（68．6±1．8）个月和（57．4±3．4）个月，三者间差异有统计学意义（P〈0．001）。多因素分析显示，EZH2表达情况、淋巴结转移情况和肿瘤分期为影响SCC预后的独立因素。结论EZH2和p53蛋白表达可能参与了SCC的发生和发展，其与SCC是否发生淋巴结转移及预后有关。
Objective To investigate the expression and clinical significance of enhancer of zeste homolog 2 （EZH2） and p53 proteins in cervical squamous cell carcinoma （SCC） and cervical intraepithelial neoplasia （CIN）. Methods The expression and distribution of EZH2 and p53 were determined with reference to clinicopathological features and patient survival. 168 cervical SCC, 19 CIN II, 35 CIN Ⅲ patients and 30 normal control cases were collected for immunohistochemical analysis. Results The expression of EZH2 in the normal cervix, CIN and SCC was 6.7% （2/30）, 37.0% （20/54） and 75.6% （127/168）, respectively, with a significant difference between them （P 〈 0.05 ）. The expression of p53 was 3.3% （1/30）, 20.4% （11/54） and 39.3% （66/168）, respectively, also （P〈0.05）. In the 168 SCC cases, the positive rate of EZH2 in the cases with lymph node metastasis was 82.9%, and that of p53 was 45.7% ; the positive rate of EZH2/p53 protein expression in the cases with negative lymph nodes was 70.4%, and that of p53 was 34.7%, with a significant difference between the two subgroups （ P 〈 0.05 ）. Among the 143 followed-up SCC patients, the EZH2^＋ p53 ^＋ cases had a progression-free survival of （51.3 ± 3.8） months, that of EZH2^＋ or p53 ^＋ cases was （66.1 ±2.0） months, and that of EZH2 ^- p53^ - cases was （71.3 ±1.9） months, with a very significant difference among the three subgroups （ P 〈 0. 001 ）. The overall survival times of EZH2^- p53 ^-, EZH2^＋ or p53 ^＋ , and EZH2 ^＋ p53^＋ cases were （72.9 ±＋ 1.1 ）, （68.6 ± 1.8）, and （57.4 ±＋3.4） months, respectively, with a significant difference among the three subgroups （P 〈 0. 001 ）. The multivariate analysis showed that EZH2 expression, lymph node metastasis and tumor staging were independent prognostic factors. Conclusions Both EZH2 and p53 proteins may play important roles in the occurrence and development of cervical squamous cell carcinoma. There is a close relationship between the expression of both EZH2 and p53 proteins and the prognosis of SCC patients.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2014年第8期597-601,共5页
Chinese Journal of Oncology
基金
广东省科技计划项目（20128031800068）
中山大学5010研究计划项目（2007010）
